Blocks revival rolls on with £115m Syncona sale

Risk appetite in the equity blocks market in Europe has improved significantly, according to market sources, and a UK biomedical research charity is the latest vendor to take advantage of the better conditions by offloading a chunk of its stake in Syncona, the FTSE 250 life sciences investment company.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: